How Drugs Actually Work: A Listener's Guide to Pharmacology

Most people take medication without a detailed understanding of what it’s doing at the molecular level, which is entirely reasonable — except when that gap in knowledge leads to poor adherence decisions, unexpected side effects that could have been anticipated, or blind trust in systems that have historically been less reliable than they appear. The show has built a serious collection of pharmacology and medical science episodes that bridge that knowledge gap without requiring a biochemistry background. These eight episodes cover the full arc from how new drugs are discovered to how individual drugs behave in individual bodies.

The Platform That Changed Everything

The mRNA Revolution: How Scientific Grit Saved the World is the origin story of a drug delivery platform that could reshape medicine for decades. Katalin Karikó spent forty years developing modified nucleoside mRNA technology in the face of institutional indifference, grant rejection, and demotion — and the COVID-19 vaccines were built on the foundation she constructed. The episode explored what mRNA therapeutics actually are (instructions delivered inside a lipid nanoparticle, not genetic modification), why the modified nucleoside insight was so critical (it prevented the immune system from destroying the mRNA before it reached its target), and what the platform enables beyond COVID vaccines: cancer immunotherapy, rare genetic disease treatment, and rapid-response vaccine manufacturing. Understanding the platform contextualizes not just COVID vaccine technology but the next generation of drugs currently in clinical trials.

The Discovery Problem

From Code to Cure: How AI is Redefining Drug Discovery examined the fundamental bottleneck in pharmaceutical development: finding molecules that interact with a biological target in the desired way is an almost incomprehensibly large combinatorial search problem. Traditional drug discovery relies on high-throughput screening of existing compound libraries — expensive, slow, and biased toward chemical space that’s already been explored. AI-driven generative chemistry designs novel molecules from first principles, predicts binding affinity and toxicity before synthesis, and has already produced drug candidates for targets that resisted conventional approaches for decades. The episode covered specific examples — including an AI-discovered antibiotic class effective against resistant organisms — and examined what the pathway from AI design to clinical approval actually looks like.
The Silent Pandemic: Can AI Solve Antibiotic Resistance? focused the drug discovery conversation on its most urgent application. Antimicrobial resistance is projected to kill more people annually than cancer by 2050, yet antibiotics are commercially unattractive because they’re taken for short courses and need to remain on the shelf rather than being used. The episode examined the “Red Queen’s Race” biology of resistance, why traditional discovery pipelines have largely abandoned antibiotic research, and how AI-assisted approaches — including the discovery of Halicin against pan-resistant bacteria — might change that calculus. It’s an episode where the scale of the problem and the potential of the solution are genuinely proportionate.

How Drugs Get Approved

Beyond the FDA: Why Small Nations Re-Review Medicine explored a question that pharmaceutical nationalism complicates: if the FDA and EMA have reviewed a drug and approved it, why does Israel (or any other country) conduct its own review? The episode traced the legitimate scientific reasons — population-specific pharmacogenomic differences, local disease burden patterns that may affect the benefit-risk calculus, manufacturing standards verification — and the less defensible ones, including protectionist pressure from domestic pharmaceutical interests. It also covered what drug approval reform could look like and why the current system creates access delays that have real health consequences for patients waiting for drugs available elsewhere.

What Goes Wrong With Long-Term Use

The Polypharmacy Puzzle: How Many Pills Are Too Many? addressed the mathematical reality of multiple concurrent medications. Each additional drug added to a regimen multiplies interaction risk in a non-linear way; above five medications, the number of potential pairwise interactions exceeds what any clinician can track mentally. The episode covered the research on polypharmacy outcomes in older adults, the most clinically significant interaction classes, and the concept of “deprescribing” — the systematic process of reviewing and reducing medication burden, which has its own evidence base showing improved outcomes when done carefully.
The PPI Paradox: Long-Term Risks of Acid Blockers examined one of the most common examples of a medication that migrates from short-term to indefinite use without a clear clinical decision being made. Proton pump inhibitors are prescribed for weeks and taken for years by millions of people, and the research on long-term use has identified real risks: hypomagnesemia, impaired calcium absorption and increased fracture risk, Clostridioides difficile susceptibility, altered gut microbiome composition, and vitamin B12 malabsorption. The episode covered the epidemiology of these risks, the subpopulations most exposed, and when discontinuation is clinically appropriate.

The Fallibility of Medical Knowledge

Will Today’s Medicine Look Barbaric in 80 Years? examined the epistemological problem at the heart of medical practice: current evidence-based medicine is the best we have, but historical evidence-based medicine included insulin coma therapy, tonsillectomies for most childhood sore throats, and routine episiotomy. The episode traced the mechanisms by which medical consensus changes — the role of commercial interests in research funding, the publication bias toward positive findings, the inertia that keeps discredited practices in guidelines — and examined what this implies for how to evaluate current medical recommendations. The answer isn’t skepticism of medicine, but a more sophisticated engagement with what “evidence-based” actually means.

The Tapering Science

Beyond the Pill: The Science of Tapering Sleep Meds addressed the pharmacology of discontinuing sleep medications, specifically Seroquel (quetiapine) used off-label as a sleep aid. The episode covered the histamine H1 receptor antagonism that produces quetiapine’s sedating effect at low doses, the receptor upregulation that occurs with chronic use, and why abrupt cessation produces a rebound insomnia that can be significantly worse than the original sleep difficulty. The “hyperbolic tapering” approach — reducing doses in small percentage decrements rather than fixed milligram steps, because receptor occupancy changes non-linearly with dose — emerged from the research on minimizing discontinuation effects and is explained clearly enough to be actionable.

These episodes share a commitment to explaining not just what a drug does but how it does it — because the mechanism is what makes the clinical advice intelligible rather than arbitrary. A patient who understands why Singulair takes two weeks, or why an antibiotic needs to be finished even after symptoms resolve, is more likely to use their medication in a way that actually delivers the benefit it was prescribed for.